SETTLEMENT G	RID¹
--------------	------------------------

Condition	Age at Diagnosis				
VHD ²	<u><</u> 30	31-40	41-50	51-64	65+
I	10,000	8,500	7,500	6,500	5,000
II	25,000	23,500	22,500	21,000	20,000
III	95,000	85,000	75,000	70,000	65,000
IV	350,000	300,000	250,000	175,000	100,000
V(a)	500,000	425,000	300,000	200,000	125,000
$V(b)^3$	625,000	550,000	425,000	325,000	225,000

PPH ⁴	<u><</u> 30	31-40	41-50	51-64	65+
	400,000	350,000	275,000	200,000	125,000

- a) whether there are dependents with exceptional needs;
- b) exceptional economic loss;
- c) exceptional cost of future care; and
- d) other exceptional factors.

⁴ **Supplementary PPH Benefits:** Claimants who qualify for PPH benefits shall be entitled to an additional \$15,000 per year, to a maximum of \$75,000:

- a) for each additional year that the Product Recipient lives with the condition beginning five years after diagnosis with PAH; or
- b) where a Product Recipient has had a lung transplant within five years of diagnosis with PAH as a result of the PPH, from the time of transplantation.

¹ **Derivative Claims:** For claims at Matrix level II and higher, Eligible Derivative Claimants will be entitled to receive benefits from the Derivative Claims Fund as set out in section 9(f) of the Settlement Agreement.

² **FDA Positive Claims:** Compensation for FDA Positive claims shall be paid from the FDA Positive Fund with the maximum benefit for any single claim not to exceed \$2,500.

³ **Supplementary Matrix Level V Benefits:** Claimants who qualify for Matrix Level V will be compensated at Matrix Level V(a) unless they can demonstrate exceptional hardship. In considering whether the existence of exceptional hardship has been established, Justice Winkler may consider: